Ireland Pharmaceutical Licensing

This guide discusses only commercial activities involving human medicines in Ireland. Relevant official pages identify the competent authorities as the national-level PSI, HPRA, CRO, and health authorities; the rules and MIA scope for human medicines may differ from those for veterinary medicines and investigational medicinal products, so the product and activities should first be defined.

Incorporating a company or establishing a branch of an overseas company is a company-law registration matter for the CRO. An overseas company establishing a branch in Ireland must register with the CRO under Part 21 of the Companies Act 2014, but CRO registration does not replace RPB, WDA, MIA, marketing authorisation, or controlled-drug licences.

The official materials reviewed in this round do not specify a uniform foreign shareholding limit, minimum capital amount, mandatory company form, or nationwide minimum premises-area threshold applicable to all three types of human-medicine business authorisation. Anyone proposing to use overseas shareholders, a branch, or a complex holding structure should confirm the position with both the CRO and the relevant licensing authority before the transaction.

— Retail to the public: RPB.

— Procurement, storage, supply, or export not involving supply to the public: WDA.

— Manufacturing, packaging, batch certification, or actual importation from outside the EU/EEA: MIA.

— Product marketing, individual practice, controlled drugs, and company registration are handled separately.

The Pharmacy Act 2007 establishes the framework for pharmacist and pharmacy registration and contains rules on registration and inspection of retail pharmacy businesses and on pharmacy businesses operated by individuals, partnerships, and companies. The PSI administers RPB and pharmacist registration under this Act.

The HPRA authorises wholesale distribution, manufacture, and importation of human medicines and conducts GDP/GMP inspections; its product authorisation page states that Irish product authorisations (PAs) are granted under the Medicinal Products (Control of Placing on the Market) Regulations 2007. Controlled drugs are also regulated under the Misuse of Drugs Acts and the 2017 Regulations.

— PSI: retail pharmacy businesses and pharmacist registration.

— HPRA: WDA, MIA, GMP/GDP, product authorisations, and the controlled-drug administration framework.

— CRO: registration of companies or eligible overseas branches.

To operate a pharmacy lawfully in Ireland, it must first be registered as an RPB. Opening a new pharmacy, permanently relocating an existing pharmacy, and a change of ownership of an existing pharmacy may each require an initial registration; an application should be submitted at least 60 days before the planned registration and opening, and the PSI will arrange or determine the inspection method only after receiving a complete and valid application.

Applicants submit address, ownership, premises, services, and personnel details through the PSI registration portal and upload professional indemnity insurance, a layout plan, and a location map. Completion of an inspection does not mean that registration has been granted; final review is still required.

A retail pharmacy may temporarily relocate in certain circumstances, but a permanent relocation requires a new initial registration application; a material change to the layout may also require PSI approval.

— Complete RPB registration before operating a pharmacy for the public.

— The certificate and Supervising Pharmacist certificate must be displayed prominently in the pharmacy as required by the PSI.

— Publicly available pharmacy register information includes the name, address, owner, the two pharmacist roles, and certificate expiry date, among other details.

Wholesale distribution of human medicines includes procurement, holding/storage, supply within the EEA to persons other than the public, and export outside the EEA. An HPRA WDA must be obtained before carrying out these activities. Brokerage activities do not involve actually owning or handling medicines, and a WDA must not be assumed to replace any applicable authorisation merely because of the similarity of the terms.

A new WDA application is assessed by the HPRA and includes a GDP inspection of the site. The application materials cover the complete application and declarations, company evidence, distribution model, temperature control/risk assessment, premises and equipment, quality system, personnel, outsourced service providers, and proof of payment of the fee. The authorisation is recorded as an electronic WDA in EudraGMDP.

After authorisation, the HPRA continues to conduct routine inspections for GDP compliance. Proposed changes to a licensed wholesale site or distribution model require an administrative or technical variation application; a technical variation may trigger a GDP inspection.

— Set out the actual activities, customer types, supplier types, and transport model in the application design.

— Where holding or transport involves temperature control, submit the relevant temperature mapping and risk assessment.

— Where contract premises, a contract RP/DRP, or a contract transporter is used, retain the required written confirmations, audits, and technical agreement documentation.

Manufacturers/importers of human medicines must obtain an HPRA MIA and comply with GMP and the relevant EU and Irish legislation before certifying or releasing products that they have processed or imported. Activities covered by an MIA may include processing, packaging, relabelling, serialization, actual importation from outside the EU/EEA, and batch certification for the EEA market; the actual scope is as specified in the approved authorisation annex.

The HPRA encourages those planning to build a facility to request a pre-submission meeting at an early stage. Its new MIA guidance requires prospective holders to demonstrate compliance with GMP principles, and a GMP inspection is generally conducted. Once ready for inspection has been confirmed, obtain and submit the application form. The 90-day period for reviewing the application is suspended while the HPRA awaits additional information. This is a regulatory processing framework, not a guarantee of the overall project duration.

A satisfactory inspection may result in a GMP certificate; after authorisation, routine or for-cause inspections continue on a risk basis. If the GMP standard is significantly deficient, the HPRA may record a statement of non-compliance in EudraGMDP.

— Support the application with a Site Master File, quality system, qualification of equipment/premises, and the proposed activities.

— The application must list at least one QP; submit the QP’s qualification, CV, and site-training documentation in accordance with HPRA guidance.

— Whether the same authorisation covers multiple units or addresses depends on the quality system, key personnel, and approved scope; they must not be combined at your own discretion.

For a retail pharmacy, the Superintendent Pharmacist has personal control over the management and administration of the medicines sales and supply element, while the Supervising Pharmacist is in full-time charge of the business at the pharmacy premises. Both appointments require PSI registration, at least three years of appropriate post-registration experience, and completion of the portal declaration. Notify the PSI immediately of a vacancy; appointment of a successor is handled through the portal.

Having a pharmacy qualification does not automatically confer the right to practise in Ireland. Applicants with EU/EEA qualifications must first complete qualification recognition and then apply for PSI registration; the PSI emphasises that recognition of a qualification does not itself automatically confer the right to practise. For non-EU/EEA pathways, language and documentation requirements, consult the PSI pages according to the applicant’s circumstances.

An MIA must list at least one QP; a WDA application must list roles such as RP and DRP. This record does not make unverified generalisations about the educational qualifications, nationality, or on-site attendance ratios for different roles; refer to the guidance for the specific authorisation application and the scope of the business.

— Pharmacy: PSI-registered Superintendent Pharmacist and Supervising Pharmacist.

— Manufacturing: at least one QP listed in the MIA, and production/quality control heads as required by the activities.

— Wholesale: the application materials must identify the RP, DRP, warehouse management, and quality personnel.

For a first-time RPB registration, the layout plan must identify the overall pharmacy, dispensing area, pharmacist-supervised medicines storage area, consultation area, professional services area and retail area, medicines/records storage area, and dimensions. The PSI service page cited here does not provide a nationally applicable minimum floor-area figure; therefore, no area threshold should be entered without verification.

A WDA requires a physical site that is continuously accessible and adequately equipped. The quality system should cover storage, inventory control, picking, cold chain, and security; the site’s registered legal address should match the CORE and EMA SPOR records. For an MIA, GMP site documentation such as a Site Master File must be provided; the scope of the actual inspection depends on the complexity of the activities.

All premises should have inspectable records, a quality system, storage controls, and security controls appropriate to their business activities. Additional security, storage, and record-keeping requirements also apply to controlled drugs.

— Retail: prepare dispensing, consultation, and storage areas in accordance with PSI layout and inspection requirements.

— Wholesale: control premises, equipment, temperature, transport, and the outsourcing chain in accordance with GDP.

— Manufacturing: control premises, equipment, materials, laboratory, and quality system in accordance with GMP.

An RPB uses the PSI registration portal. A complete application is reviewed first; the PSI may arrange an on-site inspection or self-declaration. Any remediation identified during an inspection must be completed before the application proceeds to final registration review. Where a company owns the pharmacy, the application also requires the relevant company incorporation and constitutional documents.

A WDA application is made using the HPRA application form and new application/variation guidance. The HPRA acknowledges receipt and provides a reference number; only after review, inspection, and resolution of outstanding matters will it issue an electronic WDA and a GDP certificate or a non-compliance certificate in EudraGMDP.

The MIA process comprises HPRA pre-submission, preparation for inspection, application, GMP inspection, and authorisation steps. To market a product, separately select the Irish national procedure, DCP, MRP, or centralised procedure according to the product and market scope; do not use a product dossier in place of a premises authorisation application.

— Submit through the relevant portal or channel specified by the HPRA, and respond to requests for further information and inspection findings.

— Carry out the relevant activities only once the relevant authorisations, product status, and specific permits are all in place.

The PSI public fee schedule effective from 1/5/2026 shows an initial RPB registration fee of €4,297 and an annual continued registration fee of €2,759; the expedited surcharge for late initial registration is €1,292, and the late continued registration fee is €646. The fee schedule also lists phased amounts for subsequent years. The applicable statutory fee schedule and portal requirements must be checked at submission.

The RPB certificate is valid for 12 months. The window for applying for continued registration opens 60 days before the certificate expires; submitting fewer than 30 days before expiry incurs a late fee. Failure to submit by the expiry date will initiate cancellation and removal from the RPB register.

HPRA charges applicable fees for new WDA, MIA and product authorisation applications, variations and transfers, among other matters, and requires applicants to identify the correct category using the Human Products Fee Guide. Fees vary according to site, facility size, technical/administrative variation and product category; this record does not invent a single standard amount.

— New MIA application: HPRA guidance specifies a 90-day processing framework; time spent awaiting requested information is excluded from the calculation.

— WDA/MIA variations: standard technical or administrative variations usually take 30 to 90 days, depending on whether further information is requested and whether an inspection is required.

— Product marketing authorisation: normally renewed after five years and, in principle, valid indefinitely after the first renewal, except where further renewals are required for medicines-safety reasons.

Swipe horizontally to view all items

An RPB must maintain annual continued registration and keep registration details, required appointments and statutory pharmacy requirements up to date. If the Superintendent or Supervising Pharmacist position becomes vacant, the owner must notify the PSI immediately and arrange a new appointment.

WDA holders must remain compliant with GDP and EU and national law. The HPRA conducts routine inspections before and after authorisation; quality systems, records, storage, transport, outsourcing and staffing arrangements must all be available for verification.

MIA holders must remain compliant with GMP. The HPRA usually conducts risk-based inspections at the time of application and thereafter; inspections assess facilities, equipment, materials, laboratories, quality systems, contamination/mix-up controls and staff training, among other matters, and require a CAPA response to deficiencies.

— Controlled drugs: separately comply with applicable annual licences or registration, security, storage, registers, and reporting of theft or unexplained loss.

An RPB owner must notify the PSI of any change of ownership. When a pharmacy business is transferred to another owning/operating company, it must be registered again. Where a pharmacy is held by a limited liability company, a transaction or series of transactions involving more than 50% of the value of its issued shares may automatically cancel the pharmacy registration 28 days after the share transfer, requiring re-registration. A change to the transaction company may also trigger re-registration even if the beneficial owner remains unchanged.

In addition to ownership, changes involving the pharmacy’s Superintendent/Supervising Pharmacist, layout, temporary or permanent relocation and registration details are handled differently: some details can be updated immediately through the portal, while others require an application and prior PSI approval; a permanent relocation requires a new initial registration.

WDA and MIA holders proposing to change an authorised site or activity must submit the relevant variation application. The public WDA/MIA pages classify variations as administrative or technical, with the latter potentially requiring a GDP/GMP inspection; a share or business transaction must not be assumed to result in automatic transfer of an authorisation.

— Retail acquisition: confirm in writing with the PSI before the transaction whether it constitutes a change of ownership and requires re-registration.

— Retail personnel/layout/relocation: follow the relevant PSI portal process.

— Wholesale/manufacturing site or activity: first assess the change and submit a WDA/MIA variation to the HPRA.

— Change of marketing authorisation holder entity: use the HPRA product authorisation transfer procedure; this is not a transfer of a WDA/MIA/RPB.

Product Authorisation (PA) is the product marketing authorisation for human medicines in Ireland, not a site or business authorisation. Products marketed only in Ireland and not subject to the centralised procedure may be submitted directly to the HPRA under the national procedure; for multiple Member States, the MRP or DCP may be used, while the EMA centralised procedure is mandatory or optional for particular medicines.

The actual importation of human medicines from outside the EU/EEA falls within the scope of an MIA. A WDA holder may import exempt medicinal products for Irish patients under its WDA, but this specific arrangement should not be generalised to mean that all imports from outside the EEA require only a WDA. Export to outside the EEA is included in the definition of wholesale dealing in human medicines, but destination, product, controlled-drug and customs requirements must also be checked.

Controlled-drug authorisations are separate from ordinary business authorisations. The manufacture of any scheduled controlled drug and the supply, import, export or possession of Schedule 1 or 2 drugs require licences renewed annually; the corresponding activities for Schedules 3, 4 and 5 use registration, which must be renewed when there are changes. Each consignment of controlled drugs imported or exported also requires a separate import/export licence or LONO, depending on the schedule.

— Product authorisation: choose the national, MRP, DCP or EMA centralised procedure according to the product and market.

— Ordinary business authorisations: obtain an RPB, WDA or MIA separately according to the actual retail, wholesale, manufacturing/import activities.

— Controlled drugs: annual licence/registration plus consignment-specific cross-border permits or LONO; these are not automatically covered by an MIA/WDA.

— Theft or unexplained loss of controlled drugs must be reported as required by the HPRA.